Recommended revisions to American Dental Association guidelines for acceptance of chemotherapeutic products for gingivitis control. Report of the Task Force on Design and Analysis in Dental and Oral Research to the Council on Therapeutics of the American Dental Association.
This paper presents suggested revisions to the American Dental Association's 1985 guidelines for acceptance of anti-gingivitis chemotherapeutic agents. The areas of study design, choice and quality control of clinical gingivitis measurements, statistical analysis, and minimum strength of effect, are addressed. The revisions articulate certain aspects of study design which were implicit in the 1985 guidelines, clarify language on cross-over designs and independence of studies, and recommend use of a United States population in at least one trial supporting a product. Separate recording and analysis of a product's effect on gingival bleeding is proposed, and quality control of clinical measurements receives enhanced emphasis. Modestly elaborated statistical reporting guidelines and strengthened approval criteria, based on size of estimated effect as well as statistical significance, are advocated.
Imrey
P B
PB
University of Illinois, Urbana 61801-3618.
Chilton
N W
NW
Pihlstrom
B L
BL
Proskin
H M
HM
Kingman
A
A
Listgarten
M A
MA
Zimmerman
S O
SO
Ciancio
S G
SG
Cohen
M E
ME
D'Agostino
R B
RB
D000571:American Dental Association; D002986:Clinical Trials as Topic / Q000592:standards*; D003627:Data Interpretation, Statistical; D004282:Documentation / Q000592:standards; D004341:Drug Evaluation / Q000592:standards*; D005891:Gingivitis / Q000188:drug therapy*; D006801:Humans; D010512:Periodontal Index; D011786:Quality Control; D012107:Research Design; D014481:United States